Name | Title | Contact Details |
---|---|---|
Andrew Quant |
Sr. Director of Information Security and Compliance | Profile |
We are Körber – an international technology group with more than 12,000 employees at over 100 locations worldwide and a common goal: We turn entrepreneurial thinking into customer success and shape the technological change. In the Business Areas Digital, Pharma, Supply Chain, and Technologies, we offer products, solutions and services that inspire. We act fast to customer needs, we execute ideas seamlessly, and with our innovations we create added value for customers. In doing so, we are increasingly building on ecosystems that solve the challenges of today and tomorrow. Körber AG is the holding company of the Körber Group.
Founded in 1904, the Fédération Internationale de Football Association (FIFA) is the umbrella organisation of its members, currently 211 national football associations. Its main objectives, enshrined in its statutes, are to develop football around the world, to stage international competitions and to protect the integrity of football (against match manipulation, doping etc.). FIFA is composed of a number of political bodies (such as the FIFA Congress and the FIFA Council) and the administration. The highest political position is the FIFA President, elected every four years by FIFAs member associations. The FIFA administration, with more than 800 people from over 60 nations, is based in Zurich. It is run by the Secretary General (CEO). FIFA stages FIFA World Cups™ in various forms such as youth, mens and womens, futsal, beach soccer or club competitions. The mens FIFA World Cup™ is not only the most popular single sporting event in the world but also the financial backbone for FIFA and its efforts to develop football worldwide. The financial success of the FIFA World Cup™ allows FIFA to run a wide range of football development programmes and to provide funds, infrastructure and know-how to its member associations through the FIFA Forward Development Programme. For more information visit our website.
The Badminton World Federation (BWF) is the international governing body of the sport of badminton, recognised by the International Olympic Committee (IOC) and the International Paralympic Committee (IPC). It was originally the International Badminton Federation (IBF) which was founded on 5 July, 1934, before being rechristened the Badminton World Federation in 2006. The purpose and objectives of BWF include regulating, promoting, developing and popularising the sport of badminton throughout the world and organising, conducting and presenting international events at the highest level. The BWFs vision is to make badminton a leading global sport accessible to all – giving every child a chance to play for life. Its mission is to lead and inspire all stakeholders; to deliver entertainment through exciting events to drive fan experience; and to create innovative, impactful and sustainable development initiatives. BWF has its headquarters in Kuala Lumpur, Malaysia, with 194 Member Associations worldwide. Poul-Erik Høyer is the BWF President and Thomas Lund is the BWF Secretary General.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.